Patents by Inventor Marc VALLEE

Marc VALLEE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN AND ADOLESCENTS
    Publication number: 20230201318
    Abstract: The disclosure features methods for treating hypophosphatasia (HPP) in a patient (e.g., a child or an adolescent having HPP) exhibiting gait impairments or decreased walking ability by administering a soluble alkaline phosphatase (sALP) to the patient and assessing improvement in the gait impairment using a modified Performance-Oriented Mobility Assessment—Gait (mPOMA-G) analysis and score.
    Type: Application
    Filed: November 21, 2022
    Publication date: June 29, 2023
    Inventors: Kenji FUJITA, Marc VALLEE, Dawn PHILLIPS
  • SUBCUTANEOUS DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
    Publication number: 20210395352
    Abstract: Provided are methods for clinical treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered (or is for administration) subcutaneously according to a particular clinical dosage regimen (i.e., at a particular dose amount and according to a specific dosing schedule). In one embodiment, the patient has previously been treated with eculizumab (Soliris®).
    Type: Application
    Filed: October 30, 2019
    Publication date: December 23, 2021
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventors: Lori Volles, Rajendra Pradhan, Douglas L. Sheridan, Marc Vallee, Xiang Gao
  • CO-ADMINISTRATION OF A HYALURONIDASE AND ANTI-C5 ANTIBODY FOR TREATMENT OF COMPLEMENT-ASSOCIATED CONDITIONS
    Publication number: 20210388070
    Abstract: Provided herein are compositions and methods for treating a human patient with a complement-associated condition (e.g., PNH or aHUS) by subcutaneously co-administering to the patient a hyaluronidase (e.g., rHuPH20) and an anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab).
    Type: Application
    Filed: October 30, 2019
    Publication date: December 16, 2021
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventors: Andrew Denker, Rajendra Pradhan, Douglas L. Sheridan, Marc Vallee, Yang Dai, Xiang Gao
  • DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS) IN PEDIATRIC PATIENTS
    Publication number: 20210332147
    Abstract: Provided are methods for clinical treatment of Atypical Hemolytic Uremic Syndrome (aHUS) using an anti-C5 antibody, or antigen binding fragment thereof, in pediatric patients.
    Type: Application
    Filed: May 29, 2019
    Publication date: October 28, 2021
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventors: Lori PAYTON, Andrew DENKER, Eugene Scott SWENSON, Rajendra PRADHAN, Stephan ORTIZ, Marc VALLEE, Christian MIX, Xiang GAO
  • METHODS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN AND ADOLESCENTS
    Publication number: 20200306350
    Abstract: The disclosure features methods for treating hypophosphatasia (HPP) in a patient (e.g., a child or an adolescent having HPP) exhibiting gait impairments or decreased walking ability by administering a soluble alkaline phosphatase (sALP) to the patient and assessing improvement in the gait impairment using a modified Performance-Oriented Mobility Assessment-Gait (mPOMA-G) analysis and score.
    Type: Application
    Filed: June 27, 2016
    Publication date: October 1, 2020
    Inventors: Kenji FUJITA, Marc VALLEE, Dawn PHILLIPS